データなし
データなし
Revance Therapeutics Ticks Higher as Holder Says Crown Deal Undervalues Company
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories
Revance Therapeutics Board of Directors Recommend Stockholders Tender Their Shrs >RVNC
Press Release: Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per Share
このコンテンツを閲覧するにはログインが必要です。